Financial Data and Key Metrics Changes - The company ended 2025 with approximately $24.7 million in cash and cash equivalents and working capital of approximately $3.4 million [31] - Selling, general and administrative (SG&A) expenses for 2025 were $8.8 million, a decrease from $9.2 million in 2024, primarily due to lower stock-based compensation and personnel costs [32] - Research and development (R&D) expenses were reported at $5.5 million for 2025, down from $14.3 million in 2024, with contra-R&D expenses reflecting grant dollars received at $13.9 million in 2025 compared to $7.7 million in 2024 [32][33] Business Line Data and Key Metrics Changes - The company is advancing multiple programs simultaneously, including DARE to PLAY, which is expected to begin generating revenue in Q2 2026 [33] - DARE to RESTORE products, including Flora Sync LF5, are expected to be commercially available in the U.S. consumer health market in the second quarter of 2026 [16][27] - DARE to RECLAIM is targeting 503B commercial availability in 2027, while Ovaprene is in a phase III pivotal trial with enrollment expected to complete in 2026 [18][20][27] Market Data and Key Metrics Changes - The company is addressing a significant market gap in women's health, which has historically received only 6% of private healthcare investment, with conditions affecting women attracting less than 1% [25][30] - The estimated market for DARE to RECLAIM is between $2.5 billion and $4.5 billion, targeting the compounded hormone therapy market [18] - The company is also developing DARE-HPV, which addresses a large untreated patient population with high-risk HPV infections, representing a significant market opportunity [22][24] Company Strategy and Development Direction - The company employs a dual-path strategy, commercializing proprietary formulations through 503B compounding while pursuing FDA approval for select products [2][14] - The focus is on building a comprehensive pipeline of differentiated products for women's health, addressing various conditions from contraception to menopause [5][15] - The company aims to leverage non-dilutive funding to advance its programs while managing shareholder dilution responsibly [31][33] Management's Comments on Operating Environment and Future Outlook - Management believes that 2026 will be a pivotal year for the company, showcasing the results of a decade of commitment to women's health [7][25] - The company is positioned to capitalize on the growing demand for women's health solutions, with increasing political and media attention on the subject [30] - Management emphasizes the importance of building real-world data through its commercial model to strengthen future regulatory submissions [27][28] Other Important Information - The company has received significant non-dilutive funding, including approximately $20.8 million from sales of common stock and $13.6 million from the Gates Foundation in 2025 [31] - The company is actively engaging in provider education and digital marketing to raise awareness of its products [12][49] Q&A Session Summary Question: When was your last interaction with FDA on Sildenafil Cream? - Management confirmed that interactions with the FDA occurred last year, focusing on aligning endpoints for the trial [37][38] Question: Do you need to conduct any additional safety studies? - Management stated that existing safety data would be sufficient for submission, emphasizing the localized effect of the topical formulation [43][44] Question: What are you seeing with the order patterns for DARE to PLAY? - Management reported a mix of prescriptions coming in from both brick-and-mortar providers and telehealth channels, indicating strong interest [46][47] Question: How do you envision the bigger driver of volume for DARE to PLAY? - Management is evaluating various platforms and partnerships to ensure effective patient acquisition and reach [57][58] Question: How are you thinking about promoting DARE to RESTORE? - Management plans to leverage digital marketing and provider engagement to create awareness and drive conversion for DARE to RESTORE [51][53]

Financial Data and Key Metrics Changes - The company ended 2025 with approximately $24.7 million in cash and cash equivalents and working capital of approximately $3.4 million [31] - Net proceeds from sales of common stock were approximately $20.8 million, with non-dilutive capital contributions totaling approximately $19.4 million from various grants [31] - Selling, general and administrative expenses decreased to $8.8 million from $9.2 million in 2024, while research and development expenses dropped to $5.5 million from $14.3 million in 2024 [32][33] Business Line Data and Key Metrics Changes - The company is advancing multiple programs simultaneously, including DARE to PLAY, which is expected to begin generating revenue in Q2 2026 [33][34] - DARE to RESTORE, a line of consumer health products, is expected to become commercially available in the second quarter of 2026 [16][27] - DARE to RECLAIM is targeting 503B commercial availability in 2027, while Ovaprene is in a pivotal phase III trial with enrollment expected to complete in 2026 [18][20][27] Market Data and Key Metrics Changes - The company is addressing a significant market gap in women's health, which has historically received only 6% of private healthcare investment [25] - The estimated market for bioidentical hormone therapy is between $2.5 billion and $4.5 billion, with DARE to RECLAIM positioned to enter this market [18] - The contraceptive market is shifting towards non-hormonal options, with Ovaprene targeting this growing demand [19] Company Strategy and Development Direction - The company employs a dual-path strategy, commercializing proprietary formulations while pursuing FDA approval for select products [2][12] - The focus is on building a comprehensive pipeline of differentiated products for women's health, addressing conditions that uniquely affect women [5][15] - The company aims to leverage digital marketing and telehealth to drive consumer awareness and access to its products [12][29] Management's Comments on Operating Environment and Future Outlook - Management believes that 2026 will be a pivotal year for the company, showcasing the results of a decade of commitment to women's health [7][25] - The company is positioned to capitalize on the rising cultural and commercial focus on women's health, with a robust pipeline ready to meet market demands [30][75] - Management emphasizes the importance of building real-world data to support future regulatory submissions and strengthen market position [27][28] Other Important Information - The company has received significant grant funding, which has allowed it to advance its R&D efforts without diluting shareholder equity [31][33] - DARE to PLAY is the first topical arousal cream for women backed by clinical data, addressing a previously unmet need in the market [8][11] Q&A Session Summary Question: When was the last interaction with FDA on sildenafil cream? - Management confirmed that interactions occurred last year, focusing on aligning endpoints for the trial [37][38] Question: Do you need to conduct additional safety studies? - Management indicated that existing safety data would be sufficient for submission, emphasizing the localized effect of the topical formulation [43][44] Question: What are you seeing with the order patterns for DARE to PLAY? - Management reported a mix of prescriptions coming in from both brick-and-mortar providers and telehealth channels, indicating strong interest [46][47] Question: How do you envision the bigger driver of volume for DARE to PLAY? - Management is evaluating various channels, including telehealth and prescriber education, to maximize reach and patient acquisition [57][59] Question: How will you convey the formulation differences of DARE to PLAY? - Management highlighted the importance of clinical data and the unique formulation technology to differentiate from compounded products [61][64]

Core Insights - Mayne Pharma Group Limited is focusing on women's health and dermatology markets in the United States, with a strategy aimed at expanding access to its products and enhancing patient outcomes [1][3] Business Units - The company operates across three business units, with two generating all revenue from the US, specifically targeting women's health and dermatology, while the third unit covers Australia and other global markets [2] Women's Health Portfolio - Mayne Pharma's women's health portfolio includes four reproductive health products that address contraception and menopause treatment, which are described as "best in class" [2][3] - Innovations in this portfolio include plant-derived estrogen therapies and combination drug-device solutions aimed at improving patient access and outcomes [3] Dermatology Products - The company offers 31 dermatology products targeting conditions such as psoriasis and acne, and has maintained profitability despite challenges in insurance reimbursement [3] Financial Performance - In the first half of the year, Mayne Pharma reported $212 million in revenue and generated $16.9 million in operating cash flow, which were characterized as "very resilient" results in a challenging environment [3] Future Focus - Looking ahead, the company aims to expand access strategies, strengthen its salesforce, and capitalize on growth opportunities in the US hormone replacement therapy market [4] - Mayne Pharma has strong fundamentals, including patent protection and growing market share, with significant potential to capture more market share [4]

Company Overview - Daré Bioscience, Inc. is a health biotech company focused on women's health, aiming to bridge the gap between scientific advancements and practical solutions [3][4] - The company is dedicated to developing evidence-based solutions for various women's health issues, including contraception, menopause, pelvic pain, fertility, vaginal health, and infectious diseases [3][4] Upcoming Events - Daré Bioscience will host a conference call and live webcast on March 26, 2026, at 4:30 p.m. Eastern Time to review its financial results for the year ended December 31, 2025, and provide a company update [1] - Access to the conference call can be made via phone or through a live webcast available on the company's investor relations website [2] Company Mission and Recognition - The company aims to accelerate the development of credible, science-based solutions that adhere to high clinical standards, including randomized controlled trials and peer-reviewed research [4] - Daré Bioscience's leadership has received recognition in the industry, with mentions in Medicine Maker's Power List and Endpoints News' Women in Biopharma, and its CEO has been honored as one of Fierce Pharma's Most Influential People in Biopharma [5]

On this International Women's Day, and to honor Women's History Mont We're shedding light on a health issue that impacts women across the globe. Uterian fibroids, benign tumors that are found in the uterus. More than 80 % of African-American women and approximately 70 % of white women will have uterine fibroids by age 50, according to the National Center for Biotechnology Information.Academy Award-winning actress, producer, and author Lupita Nyong'o has spoken out about her struggle with the condition and s ...

A mother once begged me to let her four-year-old daughter die. I was working as a pediatrician in a busy government hospital, used to the cries, the chaos, and the constant emergencies, but never this. Please, doctor, she said, give us some comfort, but let her die.I froze. How could any mother possibly say that. How could any mother lose hope so completely.And then I saw Remy, a severely malnourished little girl, terrified, screaming in frustration, hitting her mother, pulling her hair. Remy was completely ...

[music] I died. Yes. My heart completely stopped for 37 seconds.It happened right after I gave birth to my second child. What was supposed to be one of the most happiest moments of my life became one of the scariest. Thankfully, I survived. My baby survived.But that moment changed everything for [clears throat] me because instead of soaking in those first moments, that smell of my newborn, the sound of his tiny breath, I did what most working moms do. I asked for my phone. I checked in on my team.I even too ...

[music] [music] [music] Inside this box is something that many of us were never fully taught to understand, let alone celebrate. It was left out of the textbooks, the classrooms and upbringing. The clitoris pure.Yeah. She is purely built for pleasure and it's the most forgotten organ in the female body. And not because it's small, but because society decided it didn't matter.And yet, it's the key to women's well-being, empowerment, and healing. It's a symbol for women's health, for education, and for gender ...

Core Insights - The FDA has approved Organon & Co.'s NEXPLANON for extended use up to five years, enhancing its contraceptive indication from three years [1][7] - Clinical trial data supports the efficacy of NEXPLANON, showing no pregnancies during years four and five, and effectiveness across various body weights [2][5] Company Developments - The approval of NEXPLANON is a significant advancement for women seeking reliable and long-lasting contraception, demonstrating Organon's commitment to inclusive healthcare [3][11] - Organon has introduced a new Risk Evaluation and Mitigation Strategy (REMS) program to ensure proper provider training for the insertion and removal of NEXPLANON [9][10] Market Positioning - The five-year indication for NEXPLANON improves its competitive positioning against other long-acting contraceptive options, enhancing convenience and long-term adoption [5][11] - Organon's current market capitalization stands at $2.28 billion [6] Industry Outlook - The women's health therapeutics market is projected to reach $48.57 billion by 2026, with a CAGR of 4% through 2035, driven by increasing women's health issues [12] - The partnership with Daiichi Sankyo Europe to market Nilemdo expands Organon's cardiovascular portfolio, addressing a significant healthcare gap for women [13] Additional Developments - Organon has received FDA approval for POHERDY, a biosimilar to the cancer drug PERJETA, enhancing patient access to affordable cancer treatments [14]

Core Insights - Daré Bioscience, Inc. has received approximately $3.6 million from the Gates Foundation to support the development of a non-hormonal intravaginal contraceptive aimed at women in low- and middle-income countries [1][2][3] Funding and Grant Details - The recent payment is part of a larger grant agreement totaling approximately $10.7 million, originally announced in November 2024, reflecting the company's achievement of key development milestones [2][4] - An initial payment of approximately $5.4 million was received in 2024, with future payments contingent on the achievement of additional milestones [4] Product Development Focus - The funding will support activities related to product design, formulation, acceptability, and early-stage development, which will inform subsequent clinical development [3][4] - The company is advancing its investigational hormone-free monthly intravaginal contraceptive, Ovaprene®, which is currently in a pivotal Phase 3 study [3] Company Mission and Vision - Daré Bioscience is dedicated to closing the gap in women's health by developing innovative solutions based on advanced science and rigorous research [5][6] - The company aims to provide non-hormonal, user-controlled contraceptive methods that align with women's preferences, particularly in LMIC settings [3][4]